Anticancer Drugs Medicine Oncology Pharmacology Physiotherapy Relugolix

Relugolix and Embryo-Fetal Toxicity

In this article we will discuss Relugolix and Embryo-Fetal Toxicity

In this article, we will discuss Relugolix and Embryo-Fetal Toxicity. So, let’s get started.

Relugolix and Embryo-Fetal Toxicity

The safety and efficacy of Relugolix have not been established in females. Based on findings in animals and mechanism of action, Relugolix can cause fetal harm and loss of pregnancy when administered to a pregnant female. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during the period of organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on area under the curve (AUC). Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of Relugolix.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.